Meghmani Llp logo

Meghmani Llp

Pharmaceutical company specializing in paracetamol production, part of Meghmani Group since 2010.
2010 | Ahmedabad, Gujarat (India) | Active

Last Updated:

January 21, 2024
HomeCompanyMeghmani Llp

Who are the key members and board of directors at Meghmani Llp?

Designated Partners(2)

NameDesignationAppointment DateStatus
Maulik Patel In Designated Partner 31-Mar-2010Current
Kaushal Soparkar In Designated Partner 31-Mar-2010Current

Financial Performance and Corporate Structure Insights of Meghmani Llp.

Meghmani Llp, for the financial year ended 2021, experienced significant growth in revenue, with a 30.19% increase. The company also saw a substantial improvement in profitability, with a 67.44% increase in profit. The company's net worth witnessed no change by increase of 0%.

Revenue Growth Graph
Profit Loss Graph
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metric
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
30.19%
Revenue from Operations
30.61%
Total Assets
44.32%
Profit or Loss
67.44%
Net Worth
EBITDA
30.61%

Related Corporates (Common Directorship)

Charges (Loans)

Open Charges

₹1,750.00 M

LenderAmountStatus

Icici Bank Limited

Creation Date: 12 May 2021
₹85.00 CrOpen

Hdfc Bank Limited

Creation Date: 23 Dec 2015
₹90.00 CrOpen

How Many Employees Work at Meghmani Llp?

Meghmani Llp has a workforce of 509 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Graph

Deals i

Rating

Alerts

Latest Updates, News, and FAQs on Meghmani Llp

Recent activity within the organization

  • Statement of Assets & Liabilities

    Meghmani Llp has filed its annual Financial statements for the year ended 31 Mar 2023 with RoC-Ahmedabad.

    31 Mar 2023

  • Charges

    A charge with Icici Bank Limited amounted to Rs. 850.00 M with Charge ID 100451518 was registered on 12 May 2021.

    12 May 2021

  • Charges

    A charge with Hdfc Bank Limited of Rs. 900.00 M registered on 23 Dec 2015 with Charge ID 100016678 was modified on 26 Dec 2018.

    26 Dec 2018

  • Charges

    A charge with Hdfc Bank Limited amounted to Rs. 900.00 M with Charge ID 100016678 was registered on 23 Dec 2015.

    23 Dec 2015

  • Director Appointment

    Kaushal Ashishbhai Soparkar was appointed as a Designated Partner was appointed as a Designated Partner on 31 Mar 2010 & has been associated with this company since 14 years 8 months .

    31 Mar 2010

  • Director Appointment

    Maulik Jayantibhai Patel was appointed as a Designated Partner was appointed as a Designated Partner on 31 Mar 2010 & has been associated with this company since 14 years 8 months .

    31 Mar 2010

Recent News, Updates & Announcement

Frequently asked questions

  • Meghmani Llp was incorporated on 31 Mar 2010.

  • The Obligation of Contribution of Meghmani Llp is ₹ 0.10 M.

  • Currently 2 partners are associated with Meghmani Llp.

    • Kaushal Ashishbhai Soparkar
    • Maulik Jayantibhai Patel
    Kaushal Ashishbhai SoparkarMaulik Jayantibhai Patel
  • As per Ministry of Corporate Affairs (Mca), the registered address of Meghmani Llp is 11Th Floor 'Jmc' House Eden Co-Op Hsg Offices Soc. Ltd. Opp. Parimal Garden, Ellisbridge Na, Ahmedabad, Gujarat, India, 380006.

  • The Limited Liability Partnership Identification Number (LLPIN) of Meghmani Llp is AAA-1055.

  • The Official website of Meghmani Llp is https://www.meghmanigroup.com

  • According to the financial reports for the fiscal year 2021, the revenue trend for Meghmani Llp has risen by 30.19%.

  • As Per 2021 financial reports, 509 employees are currently employed by Meghmani Llp.

  • As per the financial statements for fiscal Year 2021, The total open charges for Meghmani Llp amount to ₹ 175.00 Cr.

  • The most recent Balance Sheet for Meghmani Llp was filed with the ROC on 31 Mar 2023.

Similar Companies Based on Drug Formulation & Development